Alexion Pharmaceuticals, Inc. has received $1.1 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 1 Financial Advisor in the Stock Trading Firms. The EPS growth rate is projected at 30.95%.
Alexion Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 13.46% or $0.14 during its most recent quarterly earnings. The Actual EPS was $1.18 compared to the Estimated EPS of $1.04. New Haven based Alexion Pharmaceuticals, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Feb 16, 2017.
Alexion Pharmaceuticals, Inc. has a Price to Earnings ratio of 33.52 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 3.38. For the Most Recent Fiscal Year, Alexion Pharmaceuticals, Inc. has a price to cash ratio of 25. For the Trailing twelve month period, company showed a Net Profit Margin of 12.46% and Return on Equity of the stock is 10.58%.
In the last quarter, Alexion Pharmaceuticals, Inc. reported Annual Earnings of $1.18. Based on the filings, last years Annual Earnings was, $4.55. In the last Quarter, ALXN reported a surprise Earnings per Share of 13.46% . The consensus estimate for current quarter is $1.1 and for the current fiscal year, the estimate is $3.86. For the Next fiscal year, the estimate is $4.8 based on the consensus.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) : On Tuesday heightened volatility was witnessed in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) which led to swings in the share price. The stock opened for trading at $128.01 and hit $131.07 on the upside , eventually ending the session at $130.68, with a gain of 2.05% or 2.63 points. The heightened volatility saw the trading volume jump to 2,052,196 shares. The 52-week high of the share price is $162 and the company has a market cap of $29,263 million. The 52-week low of the share price is at $109.12 .
Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The companys lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.